Clinical trials: CKD Stage 4
Chronic Kidney Disease
Chronic Kidney Disease Among Frail Elderly
Chronic kidney disease is a common diagnosis in the elderly population and it is associated with significant morbidity and health care costs. The prevalence rates increase with age to about 40% for adults aged > 65 years.
- Trial name
- FRED-CKD (NCT02351349)
- Testing
- multidisciplinary intervention
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Sameena Iqbal
We Investigated the Relationship Between Plasma FGF23 Levels and Endothelial Dysfunction in a Sizable Series of Incident Stage 3-4 CKD Patients.
Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD)
Vascular calcification and endothelial dysfunction (ED) contribute to the development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD).
- Trial name
- NCT01135615
- Testing
- Sevelamer, calcium acetate
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Gulhane School of Medicine
Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2
The Life Style Patterns and the Development Trend of Chronic Diseases in Healthy and Sub-healthy Groups Were Analyzed by Using Data-mining Techniques
Used multi-year health examination member profile by multi-algorithms technology, to find comprehensive key hazard factors or important high-risk group components for metabolic syndrome and chronic kidney disease or more common…
- Conditions
- Chronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
- Trial name
- NCT05225454
- Where
- Taiwan
- Volunteers
- 81,108 people
- Sponsor
- Far Eastern Memorial Hospital
Kidney Failure, Acute, Contrast Media
Bicarbonate v Saline to Prevent Contrast Nephropathy
Slowing of kidney function occurs in a minority of people given dye during angiography. The purpose of this study is to compare two different types of fluid given into a vein to reduce the risk of kidney injury: salt in water or…
- Trial name
- NCT00384995
- Testing
- 0.9% (154 mEq/L) IV Sodium Chloride, 1/6 M (166 mEq/L) IV Sodium Bicarbonate
- Where
- 5 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Italian Society of Nephrology
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass
Coronary artery disease is a major cause of death in patients with renal dysfunction Among patients who undergo coronary artery bypass grafting ,renal dysfunction is known To be a major predictor of in-hospital and remote…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Coronary Artery Disease
- Trial name
- NCT01410617
- Testing
- hemodialysis
- Where
- Iran
- Volunteers
- 120 people
- Sponsor
- Imam Khomeini Hospital
Patients With Stage 2-4 Chronic Kidney Disease
Lifestyle Modifications and the Progression of Chronic Kidney Disease
Aerobic training has been shown to favorably alter several of the known risk factors for coronary artery disease including hypertension, dyslipidemia, obesity, and diabetes (1).
- Trial name
- NCT01179906
- Testing
- Exercise training, Diet modification
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Springfield College
Hypertension, Renal Insufficiency, Chronic
A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.
The purpose of this research study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to the background antihypertensive therapy in patients with uncontrolled blood pressure and chronic kidney…
- Trial name
- INSPIRE-CKD (NCT04162366)
- Testing
- Aprocitentan 25 mg
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Hemodialysis
STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE
We wanted to test the hypotheses that blood pressure level was lower, that the variability of blood pressure and blood glucose was reduced, and that quality of life was improved when glucose was added to the dialysis fluid.
- Trial name
- NCT00278057
- Testing
- dialysisis with and without glucose in the dialysis
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Regional Hospital Holstebro
Anemia
A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy
This single arm, open label study will assess the efficacy, safety and tolerability of methoxy polyethylene glycol-epoetin beta for the treatment of chronic renal anemia in participants with chronic kidney disease (CKD) secondary…
- Trial name
- NCT01191983
- Testing
- Methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 14 sites in India
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Anemia
Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)
The drug that is under investigation during this study is BAY85-3934 which is intended to be used as a treatment for patients suffering from renal anemia due to chronic kidney disease (stage 3 and 4).
- Trial name
- NCT01332942
- Testing
- BAY85-3934
- Where
- 11 sites in Germany, United Kingdom
- Volunteers
- 44 people
- Sponsor
- Bayer
Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3
Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients
The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).
- Trial name
- NCT01709994
- Testing
- Aspirin
- Where
- Spain
- Volunteers
- 97 people
- Sponsor
- Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales
Renal Insufficiency, Chronic, Chronic Kidney Disease stage3
Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.
Gemini is being evaluated in a placebo controlled, single dose, escalating dose study to evaluate the safety and tolerability of intravenous Gemini in adult subjects with stage 3 or 4 chronic kidney disease.
- Conditions
- Renal Insufficiency, Chronic, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
- Trial name
- PRIME (NCT06863467)
- Testing
- Intravenous Gemini
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Revelation Biosciences, Inc
CKD, Cardiovascular Diseases
Hyperlipoproteinemia A as a Marker of Cardiovascular Risk in Patients With Stage 4 Chronic Kidney Disease
The blood level of lipoprotein A (Lp(a)) is linked to mutations in gene 6 and is associated with atherothrombotic risk and clinical manifestations such as myocardial infarction, ischemic stroke, and aortic valve calcification and…
- Trial name
- LPACKD45 (NCT07141628)
- Testing
- lipoprotein A level dosing
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Chronic Kidney Disease
Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
The purpose of this study is to gain a better understanding of calcium absorption and metabolism in patients with Chronic Kidney Disease (CKD) using calcium balance and kinetic methods.
- Trial name
- NCT01161407
- Testing
- 1500 mg/d elemental calcium as calcium carbonate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
Acute Kidney Injury
Double-Blind Placebo-Controlled CIN Trial
This double-blinded placebo-controlled study will examine the incidence and significance of contrast-induced acute kidney injury following IV iodine-based contrast material administration in subjects with stage IIIB or stage IV…
- Trial name
- NCT02467075
- Testing
- Iopamidol 300 (Contrast)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan
Anemia, Chronic Kidney Disease
20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia
The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.
- Trial name
- NCT01906489
- Testing
- AKB-6548
- Where
- 47 sites in United States
- Volunteers
- 210 people
- Sponsor
- Akebia Therapeutics
Chronic Kidney Disease (Stages 4 and 5)
Respiratory Biofeedback Added to Strengthening Training in Patients With Chronic Kidney Disease
The goal of this clinical trial is to learn whether diaphragmatic biofeedback added to respiratory muscle training improves clinical and functional outcomes in adults with chronic kidney disease.
- Trial name
- RESPI-REN (NCT07369973)
- Testing
- Diaphragmatic biofeedback combined with respiratory muscle training
- Volunteers
- 24 people
- Sponsor
- Universidad de Granada
Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring
The goal of this observational pilot study is to evaluate the investigational AK+ Guard™ software as a medical device (SaMD) for detection of moderate to severe hyperkalemia (serum potassium (K+) ≥ 6.5 mmol/L) in adults with…
- Trial name
- NCT07210021
- Testing
- AK+ Guard™ ECG Application
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- AccurKardia, Inc.
Type 2 Diabetes, Chronic Kidney Disease
Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease
The purpose of this research study is to study the effects of paricalcitol on endothelial function and inflammation, cardiovascular risk factors which are associated with patient populations that have Type 2 diabetes and Stage 3…
- Trial name
- NCT01792206
- Testing
- Zemplar
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Scott and White Hospital & Clinic
Gout, CKD Stage 1-4
The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)
This trial aims to investigate the impact of two target levels uric acid-lowering therapy (ULT) caused by hyperuricemia (HU) on kidney function and CKD progression [1] measured by eGFR and albuminuria (A) [2].
- Conditions
- Gout, CKD Stage 1-4, SUA Level (>8 mg/dL; 480 µmol/L)
- Trial name
- IMPULsKF (NCT03336203)
- Testing
- Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet
- Where
- Ukraine
- Volunteers
- 2 people
- Sponsor
- Medical Practice Prof D. Ivanov